Stockwatch: My enemy's drug failure is not my drug's success
This article was originally published in Scrip
In life sciences, big share price movements occur in response to merger and acquisition (M&A) activity, clinical trial results and regulatory events. Actual, rather than rumoured M&A is the panacea for many investors but some companies have played up to this by appearing to spend more effort stoking rumours of their impending acquisition than developing their drugs. Such is the case with Achillion Pharmaceuticals, whose cry of acquisition wolf after each of its hepatitis C virus (HCV) antiviral competitors is acquired has been accompanied by a share price rise and an inevitable fundraising by the company. It is illogical for investors to believe that any and all companies developing HCV antivirals will be acquired. Those that have been repeatedly passed over as competitors with better and more advanced products are snapped up seem to be unlikely M&A candidates, but when they shout loud enough, investors behave as if this is a maximum sum game.
You may also be interested in...
Investors in pharmaceutical companies appreciate details such as sales force dynamics, price-volume relationships and channel-stocking effects. Their absence can make investors wary.
Pandemic-related clinic closures and safety issues forced Novartis to trim its guidance slightly. But Roche, faced with more severe pandemic and biosimilar pressures, left January’s guidance unchanged.
With something for everyone in Johnson & Johnson’s second-quarter earnings report, a nudge upwards for full-year guidance could not disguise the jump down from January’s pre-pandemic expectations.